The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles.

Pembrolizumab provided clinical benefit in previously treated advanced clear cell gynaecological cancer (CCGC). A single-arm ...

Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...

"Although PD-L1 testing is standard in some cases, many patients end up on Keytruda without really benefiting,” said Faith ...

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial ...

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

Ignite Proteomics announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to ...

PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...

Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

Rather, TIL have made a decisive move toward an in-licensing strategy, bringing in a bispecific antibody called SYN-2510.

Topline data were announced from a phase 3 trial evaluating Keytruda plus Lenvima with chemotherapy in advanced gastroesophageal cancer.